A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers

Atom Therapeutics Co., Ltd1 site in 1 country90 target enrollmentJanuary 23, 2024

InterventionsPlacebo ABP-745

DrugsABP-745 Placebo

Overview

Phase: Phase 1
Intervention: Placebo
Conditions: Not specified
Sponsor: Atom Therapeutics Co., Ltd
Enrollment: 90
Locations: 1
Primary Endpoint: Incidence of treatment-emergent adverse events (Safety and Tolerability)
Status: Completed
Last Updated: 8 months ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

A randomized, double-blind, placebo-controlled, dose-escalation study will be conducted in healthy volunteers. This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ABP-745 following single (Part 1) and multiple (Part 2) oral doses.

Registry

clinicaltrials.gov

Start Date

January 23, 2024

End Date

July 29, 2024

Last Updated

8 months ago

Study Type

Interventional

Study Design

Sequential

Sex

All

Investigators

Sponsor

Atom Therapeutics Co., Ltd

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Healthy male or female volunteers, aged 18 and 55 years (inclusive) at the time of signing the informed consent form (ICF).
•Body mass index (BMI) range within 18 \~ 30 kg/m2 (inclusive), and body weight of ≥ 50.0 kg for male and ≥ 45.0 kg for female.
•Generally healthy based on medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory tests.
•Female volunteers of child-bearing potential must agree to use effective contraceptive methods from the screening period to 90 days after the last dose of the investigational product (IP).

Exclusion Criteria

•Difficulties in venous blood collection or history of dizziness when encountering blood or needles.
•Has received an experimental agent (vaccine, drug, biologic, device, blood product or medication) within 1 month or 5 times half-life (whichever is longer) prior to the first dose of IP.
•Has a history of gastrointestinal (such as duodenal ulcer, alimentary tract hemorrhage, gastro esophageal reflux disease (GERD), etc.), liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs as determined by the Investigator (or Sub-investigator).
•Has the medical history (including past and present) of other significant diseases (including but not limited to pulmonary, cardiovascular, gastrointestinal, hematological, endocrinological and metabolic disease, immunological, dermatological, malignant diseases, mental and nervous systems, and other related diseases) or any other disease/ailment at the discretion of the Investigator (or Sub-investigator).
•Any medication (prescription and nonprescription) within 14 days or 5 times the half-life (whichever is longer) prior to the first dose of IP. (Excluding oral contraceptives, or topical ointments at the discretion of the Investigator (or Sub-investigator)).
•A known history of drug abuse within 2 years before the screening; or positive drug abuse test at screening.
•Blood donation or blood loss of more than 400 mL within 3 months before the screening.
•Smoking history (≥ 5 cigarettes per day) within 3 months before the screening, or cannot abstain from any tobacco products during the study.
•Positive screening test for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C virus (HCV) antibody.

Arms & Interventions

Placebo

Intervention: Placebo

ABP-745

Intervention: ABP-745

Outcomes

Primary Outcomes

Incidence of treatment-emergent adverse events (Safety and Tolerability)

Time Frame: Up to Day 14

Secondary Outcomes

Plasma pharmacokinetic parameters including peak plasma concentration (Cmax)(Up to Day 11)
Urine pharmacokinetic parameters including amount excreted in urine over the sampling interval (Ae)(Up to Day 8)